SCHEMBL1801625

SCHEMBL1801625

O=C(O)c1nc(-c2c[nH]c3ncc(C4=C=CC=C4)cc23)cs1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 9/20 0.40
▸ CAMKK2 Q96RR4 3/20 0.40
▸ SGK1 O00141 2/20 0.40
▸ CDK8 P49336 2/20 0.39
▸ DYRK1A Q13627 3/20 0.38
▸ CLK1 P49759 1/20 0.38
▸ DYRK2 Q92630 1/20 0.38
▸ DYRK1B Q9Y463 1/20 0.38
▸ CDK2 P24941 2/20 0.37
▸ CDC7 O00311 1/20 0.37
▸ PLK4 O00444 1/20 0.37
▸ CHEK1 O14757 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ MAPK13 O15264 1/20 0.37
▸ PDPK1 O15530 1/20 0.37
▸ DYRK3 O43781 1/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ RPS6KA5 O75582 1/20 0.37
▸ PRKD3 O94806 1/20 0.37
▸ PAK4 O96013 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1799494 0.85 TNIK (0.39) CDK2NTRK1CDK5TNIKCCNT1
SCHEMBL1801258 0.84 MAP3K11 (0.46) NTRK1ROCK1TNIK
SCHEMBL1798276 0.84 NTRK1 (0.47) DYRK1ACLK1PLK4NTRK1ROS1
SCHEMBL1796715 0.82 AXL (0.61) AXLCAMKK2SGK1CDK8DYRK1A
SCHEMBL1799923 0.78 DYRK1A (0.50) AXLCAMKK2SGK1DYRK1ACLK1
SCHEMBL1801628 0.77 AXL (0.40) AXLCAMKK2SGK1CDK8DYRK1A
SCHEMBL1798123 0.75 AXL (0.37) AXLCAMKK2SGK1DYRK1ACLK1
SCHEMBL1798971 0.74 MAP4K1 (0.43) SGK1CDK2AURKAPDPK1ROCK2
SCHEMBL3348998 0.73 CAMKK2 (0.43) CAMKK2SGK1DYRK1ACDK2RPS6KA5
SCHEMBL1796713 0.72 CAMKK2 (0.43) CAMKK2SGK1AURKAMAPK8MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed
EP-2125801-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE Eisai R&D Management Co., Ltd. (JP) 2009-12-02 — — EP disclosed
WO-2008095943-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO. LTD. (JP) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE MAPK7, MAPKAPK5, MAPK13 AXL 4302/4885CAMKK2 127/4885SGK1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback